10-K: BioLife Solutions Reports Strong 2025 Revenue Growth

BioLife Solutions, Inc. reported a 29% increase in total revenue for 2025, driven by strong demand for biopreservation media products, while continuing to streamline its portfolio through strategic divestitures and acquisitions.

Summary

• BioLife Solutions is a life sciences company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry.
• Total revenue for the year ended December 31, 2025, increased by $21.6 million, or 29%, to $96.2 million, primarily driven by a 30% increase in biopreservation media products.
• Gross profit increased by 24% to $62.1 million in 2025, but gross margin decreased from 67% in 2024 to 65% in 2025 due to lower yields on biopreservation bags, increased scrap, and a less favorable product mix.
• Operating expenses rose significantly by 44% to $78.7 million in 2025, largely due to a $15.5 million IPR&D expense from the PanTHERA acquisition and increased personnel costs.
• Net loss improved from $(20.2) million in 2024 to $(4.6) million in 2025, partly due to income from discontinued operations and increased interest income.
• The company completed several divestitures (SAVSU, CBS, SciSafe, Global Cooling) and acquired the remaining 90% of PanTHERA CryoSolutions Inc. in 2025, integrating its patented Ice Recrystallization Inhibitor (IRI) GEN 2 cryopreservation technology.
• Cash and cash equivalents decreased by $58.5 million to $33.0 million as of December 31, 2025, while available-for-sale securities increased by $73.3 million to $87.1 million, reflecting a shift in investment strategy.
• Management remediated a material weakness in internal control over financial reporting identified in 2024, concluding that disclosure controls and procedures were effective as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but strategically focused report. While revenue growth and net loss improvement are positive, the decline in gross margin and significant increase in operating expenses due to IPR&D warrant careful monitoring. The strategic divestitures and PanTHERA acquisition position the company for future growth in the CGT market.

Positives

• Total revenue increased by 29% to $96.2 million in 2025, demonstrating strong top-line growth.
• Biopreservation media products revenue increased by 30% ($19.3 million) due to increased demand from customers with commercially approved therapies.
• Gross profit increased by 24% to $62.1 million in 2025.
• Net loss significantly improved from $(20.2) million in 2024 to $(4.6) million in 2025.
• Successful divestiture of SAVSU, CBS, SciSafe, and Global Cooling businesses to streamline the product portfolio and focus on higher-margin bioproduction products.
• Acquisition of the remaining 90% of PanTHERA CryoSolutions Inc. brings patented IRI GEN 2 cryopreservation technology, expected to enhance core biopreservation capabilities within the CGT market.
• Remediation of the material weakness in internal control over financial reporting, indicating improved financial controls.
• Operating activities provided $20.1 million in cash in 2025, a significant improvement from $8.4 million in 2024.

Negatives

• Gross margin decreased from 67% in 2024 to 65% in 2025, attributed to lower yields on biopreservation bags, increased scrap, and a less favorable product mix.
• Operating expenses increased significantly by 44% to $78.7 million in 2025, primarily due to a $15.5 million IPR&D expense from the PanTHERA acquisition.
• General and administrative (G&A) expenses increased by 12% ($4.9 million) in 2025, including $5.1 million in stock compensation expenses and $0.8 million in severance expenses related to former executives.
• Research and development (R&D) expense increased by 59% ($2.8 million) in 2025, driven by higher personnel expenses.
• Cash and cash equivalents decreased by $58.5 million in 2025, primarily due to investments in available-for-sale securities and capital expenditures.
• The company has accumulated significant U.S. federal Net Operating Losses (NOLs) of approximately $168.4 million, with $38.6 million set to expire between 2026 and 2037.
• A single stockholder, Casdin Capital, LLC, holds a significant percentage (12.4%) of outstanding common stock as of December 31, 2025, which could influence corporate actions.
• The company has never paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future.

Risks

• Product defects or reliability issues could lead to lost revenue, delayed market acceptance, increased costs, and reputational damage.
• Operating in a highly competitive industry with larger competitors possessing greater financial and human resources.
• Dependence on a limited number of customers (29% of 2025 revenue from three customers) and products (82% of 2025 revenue from CryoStor products).
• Operating results are expected to fluctuate significantly from period to period.
• Potential for significant charges against earnings if intangible assets and goodwill (net carrying value of $212.8 million as of December 31, 2025) become impaired.
• Ability to attract and retain key personnel is critical to success.
• Exposure to product liability claims or product recalls, which could be expensive and divert management's attention.
• Difficulties in manufacturing, including raw material availability, facility capacity, and regulatory compliance, could adversely affect expenses and product revenues.
• Dependence on single-source and sole-source suppliers, with disruptions potentially affecting the ability to manufacture and deliver products.
• Products may become subject to FDA or other regulatory approvals in the future, potentially delaying or preventing sales or increasing expenses.
• Compliance with various international governmental regulations (e.g., data privacy, anti-corruption) may incur significant expenses or lead to penalties for non-compliance.
• Healthcare reform measures could adversely affect business and financial results.
• Increasing difficulty in obtaining or maintaining adequate insurance coverage.
• Exposure to various claims, litigation, or investigations, including those related to acquired businesses.
• Negative impact from securities litigation or stockholder activism, affecting stock price, volatility, and capital deployment.
• Acquisitions expose the company to risks such as integration difficulties, lack of synergies, underperformance, and assumption of liabilities.
• Recent divestitures expose the company to ongoing risks, including retained liabilities, indemnification obligations, and potential disputes with buyers.
• Proprietary rights (patents, trade secrets) may not adequately protect technologies and products, and patent expiration could increase competition.
• Inability to protect intellectual property rights globally due to varying legal protections and enforcement costs.
• Substantial costs from litigation or other proceedings related to patent and other intellectual property rights.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties.
• Inability to protect information systems and networks from continually evolving cybersecurity risks, including breaches of third-party systems.
• The development, deployment, and use of AI technologies present new risks and challenges, including inaccurate algorithms, regulatory penalties, and competitive harm.
• Volatility in stock price and volume, potentially leading to substantial losses for purchasers.
• Significant influence of one stockholder (Casdin Capital, LLC, owning 12.4% as of December 31, 2025) on corporate actions.
• Certain provisions in the Amended and Restated Certificate of Incorporation and Bylaws, and Delaware law, could make an acquisition more difficult or prevent changes in management.
• Exclusive forum provisions in bylaws limit stockholders' ability to choose judicial forums for disputes.
• Potential for future material weaknesses in internal control over financial reporting or disclosure controls and procedures, despite current remediation efforts.
• Changes in tax laws and regulations, including international tax developments, could adversely affect financial condition and results of operations.
• Limitations on the ability to use Net Operating Loss (NOL) and tax credit carryforwards due to Internal Revenue Code provisions (e.g., Section 382 and 383).
• Disruptive events like natural disasters, geopolitical unrest, war, terrorism, or public health issues could affect supply, delivery, or demand.
• Tariffs and other trade policies could substantially impact the business.
• Unfavorable currency exchange rate fluctuations may lead to lower operating margins or reduced sales.
• Global climate change and related legal and regulatory developments could negatively affect the business.

Future Outlook

The company expects to incur continued spending related to its existing product lines and the expansion of its commercial capabilities for the foreseeable future. It actively evaluates various strategic transactions, including acquiring complementary products, technologies, or businesses to augment its existing portfolio. Management believes current cash, cash equivalents, available-for-sale securities, and cash flows from operations are adequate to meet liquidity requirements for the foreseeable future, assuming no significant additional acquisitions. The company anticipates continued regulatory approvals for Cell and Gene Therapies (CGTs) during 2026, which could support its market opportunity.

Management Comments

• "We are focused on the development, production, and commercialization of differentiated, best-in-class products and services that facilitate the manufacturing and delivery of cell and gene therapies and biologic materials."
• "Our products are designed to increase our customers product yield and efficacy."
• "We are committed to supporting our customers with strong customer service and applications expertise."
• "We leverage our numerous relationships with leading cell and gene therapy companies that use our offering of bioproduction products and services to cross-sell other parts of the portfolio."
• "We believe that our relationships and reputation could enable us to drive further incremental revenue growth through the sale of additional products and services to a captive customer base."
• "We view our team members as the key to our success."
• "We believe in an open-door policy at all levels of the organization and establish Company-wide quarterly townhall meetings to foster a collaborative, connected environment in which anyone can contribute to our success."
• "Our human capital strategy revolves around retaining top talent and maintaining high engagement across our Company."
• "We consider relations with our team members to be good and welcome feedback from all levels of the Company on how to make improvements in our business processes and Company culture."

Industry Context

StockSavvy.ai notes that BioLife Solutions operates within the rapidly expanding Cell and Gene Therapy (CGT) market, which is treating diseases once thought incurable. The Alliance for Regenerative Medicine (ARM) reported over 1,900 ongoing clinical trials globally utilizing regenerative medicine at year-end 2025, with an expected $2.0 billion in revenues over the next five years from recently developed and FDA-approved CGT therapies. This robust market growth provides a strong tailwind for BioLife Solutions' specialized bioproduction products and services, positioning the company to capitalize on the unique manufacturing challenges within this sector.

Comparison to Industry Standards

• The filing states that the life sciences industry is highly competitive and subject to rapid technological change, with many competitors being significantly larger and having greater financial, technical, research, marketing, sales, distribution, and other resources.
• No specific comparable companies, projects, or results are detailed for direct benchmarking against industry standards within the filing.

Corporate Governance

Legal Proceedings

• Not currently aware of any material adverse legal proceedings or claims in the ordinary course of business.
• A $1.4 million claim related to Global Cooling's commercial freezer products, for which the company was required to indemnify, was settled for $0.9 million in Q4 2025, fully covered by the company's insurance policy (aside from deductible).
• A $4.0 million claim related to Global Cooling's commercial freezer products, for which the company was required to indemnify, was accrued for in Q4 2024 and settled for $2.5 million in Q1 2026, fully covered by the company's insurance policy (aside from deductible).

Related Party Transactions

• The company acquired the remaining 90% of PanTHERA CryoSolutions Inc. from the PanTHERA Sellers, which included Casdin Partners Master Fund L.P., an entity related to Casdin Capital, LLC, a significant stockholder of BioLife Solutions.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity capital raises, exposure to stock price volatility, and limited influence on corporate actions due to a significant stockholder and anti-takeover provisions. No cash dividends are expected in the foreseeable future.
• Employees: Human capital strategy focuses on retention, engagement, competitive compensation, and development. Severance expenses for former executives and a reduction in force (RIF) from the Global Cooling divestiture indicate some employee impact from strategic restructuring.
• Customers: Products are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the CGT industry. Dependence on a limited number of customers poses a risk.
• Suppliers: Dependence on single-source and sole-source suppliers creates supply chain risks, potentially affecting product availability and costs.
• Creditors: The company has Term Loan obligations and must comply with associated covenants, with total debt obligations of $5.0 million as of December 31, 2025.

Next Steps

• Continue evaluating opportunities to maximize the value of product platforms through organic growth innovations, partnerships, and acquisitions.
• Focus on the development, production, and commercialization of differentiated, best-in-class products and services for cell and gene therapies.
• Actively evaluate various strategic transactions on an ongoing basis, including acquiring complementary products, technologies, or businesses.
• Seek additional financing if available cash and anticipated cash flow are insufficient for liquidity requirements, especially for acquisition-related financing needs.
• Continue to assess the realizability of deferred tax assets and adjust the valuation allowance as needed.
• Reevaluate estimated sales tax liability and timing of satisfaction each reporting period.

Key Dates

Recommendation

BioLife Solutions demonstrates strong revenue growth in its core biopreservation media products, reflecting its strategic focus on the high-growth cell and gene therapy market. The successful divestitures streamline the portfolio, and the PanTHERA acquisition adds promising technology. However, the decline in gross margin, significant increase in operating expenses due to IPR&D, and ongoing net losses suggest that the company is still in a growth and investment phase with profitability challenges. While the remediation of internal control weaknesses is positive, the stock's volatility and dependence on a limited customer base warrant a cautious 'hold' recommendation. Investors should monitor the company's ability to translate revenue growth into sustainable profitability and successfully integrate new technologies.

Keywords

Cell and Gene Therapy, Biopreservation Media, CryoStor, Bioproduction, Life Sciences, SEC Filing, 10-K, Financial Report, Acquisitions, Divestitures, PanTHERA CryoSolutions, IRI GEN 2, Cryopreservation, ThawSTAR, Sexton Biotechnologies, Corporate Governance, Risk Factors, NASDAQ: BLFS